Skip to main content
. Author manuscript; available in PMC: 2023 Mar 26.
Published in final edited form as: Lancet Diabetes Endocrinol. 2022 Jul 5;10(8):589–596. doi: 10.1016/S2213-8587(22)00141-3

Figure 1: Comparative sensitivity and PPV for any islet autoantibodies and multiple islet autoantibodies endpoints.

Figure 1:

Comparative sensitivity (A) and PPV (B) from screening multiple islet autoantibodies at two ages for type 1 diabetes risk by age 15 years in the entire T1DI cohort. Comparative sensitivity (C) and PPV (D) from screening of any islet autoantibodies for risk of type 1 diabetes by age 15 years in the entire T1DI cohort. The comparative analyses herein were used to identify optimum screening age or ages for later evaluation by direct observation. The diagonal numbers highlighted within black squares represent performance of screening at a single age. For example, in panel C, the comparative sensitivity of a result from screening of any islet autoantibodies at one age (4 years) was 46% (95% CI 43–49), whereas comparative sensitivity from screening at two ages (2 years and 6 years) was 66% (63–69). PPV=positive predictive value. T1DI=Type 1 Diabetes Intelligence.